Safety & Cardiac Risks

Ibogaine and its metabolite noribogaine have been studied for effects on cardiac ion channels. In particular, laboratory findings have drawn attention to hERG potassium-channel activity, a mechanism associated with delayed ventricular repolarization and prolongation of the QT interval. The broader concept of long QT syndrome helps explain why this measurement receives so much attention: a prolonged interval can increase susceptibility to specific dangerous arrhythmias in the wrong circumstances.

QTc is the QT interval corrected for heart rate. It is useful as a signal, but it is not a complete account of cardiac vulnerability. Correction formulas differ, measurements can vary, and an apparently reassuring single value cannot capture changing medication exposure, dehydration, illness, electrolyte shifts, or an evolving rhythm problem.

“A timeline can describe when effects may emerge; it cannot convert a cardiac risk into a predictable schedule.”

The hour-by-hour timing overview provides context for the prolonged and variable nature of reported effects. That context matters because noribogaine may remain relevant after acute subjective effects have changed, while uncertainty around individual metabolism remains substantial.

CYP2D6 is a metabolic enzyme relevant to ibogaine exposure. Medicines that inhibit CYP2D6 may change the balance or duration of ibogaine-related compounds, while inherited differences in CYP2D6 activity can add further variation. The National Library of Medicine’s CYP2D6 pharmacogenetics overview describes why enzyme activity can differ among people and why drug-drug interactions can be consequential.

Discussion of timing should also account for the possibility of lingering metabolite exposure. Resources that discuss ibogaine market and product context do not resolve identity, purity, or dose questions in an individual case, and none of those uncertainties can be assumed away.

Heart rhythm risk is also not limited to a single named medicine. A complete review reported in formal protocols typically considers prescriptions, over-the-counter products, supplements, recent substance use, and the possibility of withdrawal-related physiological stress. The Bwiti cultural context around ibogaine is distinct from clinical evidence, and cultural context should not be substituted for medical risk assessment.

Much of the available literature consists of preclinical work, case reports, small observational cohorts, and reviews that must contend with confounding. These sources can identify plausible mechanisms and serious reported outcomes, but they cannot provide a precise, universally applicable risk estimate. Small studies and unstandardized settings also make comparison difficult.

In the United States, ibogaine is listed as a Schedule I controlled substance. The DEA controlled-substances schedule reference provides the federal classification context. Legal status, research authorization, and clinical oversight are not interchangeable: a research study may have defined safeguards that do not exist in an unregulated setting.

The principles behind Ebon Phase emphasize uncertainty, evidence awareness, and plain language. Those principles are especially important here: no web page can assess personal cardiac risk, interpret an ECG, manage medication changes, or determine whether an exposure is appropriate.